Stem Cell Therapy
North America · 1 shared keyword
Updated
Reviewed by Vidhi Upadhyay
North America Newborn Genome Sequencing Market Industry Trends and Forecast to 2034: Segmented by (Program, Condition, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$679.9 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $155.7 Mn | — | — |
| 2025 (base) | $184.9 Mn | +$29.1 Mn | — |
| 2026 (forecast) | $219.4 Mn | +$34.6 Mn | +18.7% |
| 2027 (forecast) | $260.5 Mn | +$41.0 Mn | +40.9% |
| 2028 (forecast) | $309.2 Mn | +$48.7 Mn | +67.2% |
| 2029 (forecast) | $367.0 Mn | +$57.8 Mn | +98.5% |
| 2030 (forecast) | $435.6 Mn | +$68.6 Mn | +135.6% |
| 2031 (forecast) | $517.1 Mn | +$81.5 Mn | +179.7% |
| 2032 (forecast) | $613.7 Mn | +$96.7 Mn | +232% |
| 2033 (forecast) | $728.5 Mn | +$114.8 Mn | +294.1% |
| 2034 (forecast) | $864.8 Mn | +$136.2 Mn | +367.8% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $184.9 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $864.8 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 18.7% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Program, condition and end user (see all) |
| Key players | Illumina, Inc., GeneDx, Natera, Genomics England, Fulgent Genetics (see all) |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Newborn genome sequencing reads a baby's DNA to find treatable genetic conditions early, beyond standard newborn screening.
Key segments of the newborn Genome Sequencing market include program (Research Programs, National Screening Pilots and Private Testing) and condition (Metabolic, Immune and Neurological).
The falling cost of DNA sequencing, more targeted medicines, large national genome programmes and growing use of genetic results in everyday care are driving the newborn Genome Sequencing market.
Routine use of genomics in screening, pharmacy and primary care gives the newborn Genome Sequencing market large room to grow.
Data privacy concerns, limited reimbursement for some tests, shortages of genetic counsellors and complex data analysis hold back the newborn Genome Sequencing market.
The newborn Genome Sequencing market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
In the countries we cover here, medicines are approved by Health Canada (Canada)[1] and FDA (US)[2]. How care is paid for in these countries: provincial health insurance (Canada)[3] and Medicare and Medicaid (US)[4].
[1] Health Canada. Checked 14 Nov 2026.
[2] US Food and Drug Administration. Checked 14 Nov 2026.
[3] Health Canada. Checked 14 Nov 2026.
[4] Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for newborn Genome Sequencing. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in North America.
What doctors and scientists are doing in Newborn Genome Sequencing right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
From our blog
North America · 1 shared keyword
North America · 1 shared keyword
North America
North America
North America
North America
Digital Health · North America
Healthcare Services · North America
Healthcare Services · North America
Medical Devices · North America
Digital Health · North America
Medical Devices · North America